Kim Jiseon, Kang Jin Wook, Park Jae Hyun, Choi Youngju, Choi Kyung Suk, Park Ki Dae, Baek Dae Hyun, Seong Su Kyoung, Min Hong-Ki, Kim Hyung Soo
Pharmacological Research Department, National Institute of Toxicological Research, Korea Food & Drug Administration, Seoul, 122-704, Korea.
Arch Pharm Res. 2009 Jan;32(1):117-26. doi: 10.1007/s12272-009-1125-1. Epub 2009 Jan 29.
Human mesenchymal stem cells (hMSCs) have generated a great deal of interest in clinical applications. The reason is that they may have the plasticity needed to differentiate into multiple lineages and the ability to expand ex vivo. For the therapeutic applications of hMSCs to be of practical use, it is crucial to assess the efficacy and safety of hMSCs in long-term ex vivo expansion. In this study, we cultured hMSCs by population doubling (PD) 60, and investigated their growth, osteogenic and adipogenic differential abilities, change of surface markers, telomerase activity, telomere length, and gene expression related to tumorigenesis. An in vivo tumorigenesis assay was also carried out. In long-term expanded hMSCs, the cells became aged above PD 30 and their adipogenic and osteogenic differentiation potential decreased. Telomerase activity unchanged whereas telomere length decreased and karyotypes were not changed. Gene expressions related to tumorigenesis decreased in proportion as the PD of hMSCs increased. In vivo transplantation of long-term cultured hMSCs to nude mice did not result in tumor formation. These findings suggest that diverse tests for cellular therapy should be considered during the ex vivo culture of hMSCs, particularly when a prolonged and extended propagation period is required.
人间充质干细胞(hMSCs)在临床应用中引起了极大的关注。原因在于它们可能具有分化为多种谱系所需的可塑性以及体外扩增的能力。为了使hMSCs的治疗应用具有实际用途,评估hMSCs在长期体外扩增中的疗效和安全性至关重要。在本研究中,我们将hMSCs培养至群体倍增(PD)60,并研究了它们的生长、成骨和成脂分化能力、表面标志物的变化、端粒酶活性、端粒长度以及与肿瘤发生相关的基因表达。还进行了体内肿瘤发生试验。在长期扩增的hMSCs中,细胞在PD 30以上开始老化,其成脂和成骨分化潜能降低。端粒酶活性未改变,而端粒长度缩短,核型未改变。与肿瘤发生相关的基因表达随着hMSCs的PD增加而成比例下降。将长期培养的hMSCs移植到裸鼠体内未导致肿瘤形成。这些发现表明,在hMSCs的体外培养过程中,尤其是在需要延长传代周期时,应考虑对细胞治疗进行多种测试。